MX2019003338A - Tratamiento de cefalea en racimos. - Google Patents
Tratamiento de cefalea en racimos.Info
- Publication number
- MX2019003338A MX2019003338A MX2019003338A MX2019003338A MX2019003338A MX 2019003338 A MX2019003338 A MX 2019003338A MX 2019003338 A MX2019003338 A MX 2019003338A MX 2019003338 A MX2019003338 A MX 2019003338A MX 2019003338 A MX2019003338 A MX 2019003338A
- Authority
- MX
- Mexico
- Prior art keywords
- cluster headache
- treating
- subject
- treating cluster
- cgrp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen en la presente métodos para tratar o reducir la incidencia de una cefalea en racimos, por ejemplo, cefalea en racimos crónica y cefalea en racimos episódica, y/o al menos un síntoma secundario asociado con una cefalea en racimos en un sujeto que comprende administrar al sujeto un anticuerpo monoclonal que modula la vía de CGRP; también se proporcionan composiciones para uso en los métodos descritos; también se describen el anticuerpo antagonista G1 y los anticuerpos derivados de G1 dirigidos a CGRP.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662399156P | 2016-09-23 | 2016-09-23 | |
PCT/IB2017/055776 WO2018055573A1 (en) | 2016-09-23 | 2017-09-22 | Treating cluster headache |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019003338A true MX2019003338A (es) | 2019-09-26 |
Family
ID=60120093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019003338A MX2019003338A (es) | 2016-09-23 | 2017-09-22 | Tratamiento de cefalea en racimos. |
Country Status (10)
Country | Link |
---|---|
US (2) | US20180111984A1 (es) |
EP (1) | EP3515488A1 (es) |
JP (1) | JP2019529463A (es) |
KR (1) | KR20190067181A (es) |
AU (1) | AU2017331592A1 (es) |
CA (1) | CA3037661A1 (es) |
EA (1) | EA201990548A1 (es) |
IL (1) | IL265335A (es) |
MX (1) | MX2019003338A (es) |
WO (1) | WO2018055573A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
CA2943551A1 (en) | 2014-03-21 | 2015-09-24 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
WO2018055574A1 (en) | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
US10899826B1 (en) | 2018-09-13 | 2021-01-26 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for an anti-CGRP antagonist antibody |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
WO1994004690A1 (en) | 1992-08-17 | 1994-03-03 | Genentech, Inc. | Bispecific immunoadhesins |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
CA2364484A1 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
SI2263692T1 (sl) | 2002-12-24 | 2020-10-30 | Rinat Neuroscience Corp. | Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo |
ME00419B (me) * | 2005-11-14 | 2011-10-10 | Rinat Neuroscience Corp | Antigonistička antitijela usmjerena protiv kalcitonita, peptida povezanog sa genom i postupkom njihovog korišćenja |
JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
JO3330B1 (ar) | 2010-06-10 | 2019-03-13 | Lilly Co Eli | الأجسام المضادة cgrp |
ES2893073T3 (es) | 2011-05-20 | 2022-02-07 | H Lundbeck As | Composiciones anti CGRP y uso de las mismas |
CN107827982B (zh) | 2011-05-20 | 2021-07-06 | H.伦德贝克公司 | 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途 |
AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
-
2017
- 2017-09-22 EP EP17785012.0A patent/EP3515488A1/en not_active Withdrawn
- 2017-09-22 CA CA3037661A patent/CA3037661A1/en not_active Abandoned
- 2017-09-22 US US15/712,404 patent/US20180111984A1/en not_active Abandoned
- 2017-09-22 AU AU2017331592A patent/AU2017331592A1/en not_active Abandoned
- 2017-09-22 JP JP2019515980A patent/JP2019529463A/ja not_active Withdrawn
- 2017-09-22 MX MX2019003338A patent/MX2019003338A/es unknown
- 2017-09-22 EA EA201990548A patent/EA201990548A1/ru unknown
- 2017-09-22 WO PCT/IB2017/055776 patent/WO2018055573A1/en unknown
- 2017-09-22 KR KR1020197011125A patent/KR20190067181A/ko unknown
-
2019
- 2019-03-13 IL IL265335A patent/IL265335A/en unknown
- 2019-05-15 US US16/412,992 patent/US20200102377A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2017331592A1 (en) | 2019-04-11 |
US20180111984A1 (en) | 2018-04-26 |
JP2019529463A (ja) | 2019-10-17 |
IL265335A (en) | 2019-05-30 |
KR20190067181A (ko) | 2019-06-14 |
WO2018055573A1 (en) | 2018-03-29 |
US20200102377A1 (en) | 2020-04-02 |
CA3037661A1 (en) | 2018-03-29 |
EP3515488A1 (en) | 2019-07-31 |
EA201990548A1 (ru) | 2019-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019003338A (es) | Tratamiento de cefalea en racimos. | |
MX2019003337A (es) | Tratamiento para migraña refractaria. | |
MX2018003713A (es) | Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente). | |
MX2019014265A (es) | Tratamientos conjuntos triples con anticuerpos. | |
PH12016501976A1 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
PH12018501042A1 (en) | Antibodies and antibody fragments for site-specific conjugation | |
MX2020009649A (es) | Anticuerpos monoclonales contra bcma. | |
MX2020012816A (es) | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. | |
MX2018015592A (es) | Anticuerpos inhibidores de puntos de control biespecificos. | |
MX2020001272A (es) | Anticuerpos dirigidos contra interleucina-33 (il-33). | |
MX2019015738A (es) | Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos. | |
SG10201901057UA (en) | Anti-pd-l1 antibodies | |
MX370848B (es) | Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso. | |
NZ761537A (en) | Anti-human ox40l antibodies, uses & methods | |
MX2017012113A (es) | Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer. | |
MX2019002728A (es) | Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres. | |
MX2019011252A (es) | Anticuerpos anti-c5a y usos de los mismos. | |
MX2017001686A (es) | Anticuerpos anti-ceramida. | |
ZA201800804B (en) | Novel anti-human gpvi antibodies and uses thereof | |
MX2018008008A (es) | Combinacion del inhibidor hdac y anticuerpo-pd-l1 para el tratamiento de cancer ovarico. | |
NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
WO2018089807A3 (en) | Anti-cd46 antibodies and methods of use | |
SA518391028B1 (ar) | Cd37 أجسام مضادة واختبارات للكشف عن | |
MX2019009546A (es) | Anticuerpos anti-factor d y uso de los mismos. | |
EA201891528A1 (ru) | Композиции и способы обнаружения и лечения рака желудка |